Compared with standard glutathione (500 mg), LipoMicel at a lower dose (300 mg) increased iAUC and C max by ~2.49-fold and ~2.43-fold, respectively, and when dose-normalized (to a 300 mg equivalent), incremental systemic exposure and peak levels were up to ~4-fold higher, supporting greater absorption per unit dose. The findings indicate LipoMicel is a promising delivery method for oral glutathione, though the researchers added larger, long-term studies are still needed
It really just tells me that its important, again, to go over all the risks and benefits with the patients of these different medications, and just let them know, hey, this is something new, were still finding out about it, but there have been these reports of increasing the incidence, Bert told us
Young Scientific and Technical Talents Foundation of China Academy of Chinese Medical Sciences (ZZ16-YQ-001)
While percentages may vary across studies, this could be due to different dosages or different characteristics of the study population
